Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAUVID vs ACTIVELLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.
Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.
PET imaging of tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease
Treatment of moderate to severe vasomotor symptoms associated with menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause,Prevention of postmenopausal osteoporosis
18 mg intravenously once daily.
One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals; may be prolonged in patients with renal impairment.
Estradiol has a terminal half-life of approximately 12–14 hours following transdermal administration. Norethindrone has a terminal half-life of approximately 8–10 hours. The combined product achieves steady-state within 3–5 days.
Not metabolized; eliminated primarily by renal excretion as intact drug
Estradiol is metabolized primarily in the liver via CYP3A4 and other CYPs, as well as by 17β-hydroxysteroid dehydrogenase and sulfotransferases. Norethindrone acetate is metabolized in the liver, primarily via reduction and conjugation, with CYP3A4 involved in some oxidative metabolism.
Primarily renal excretion as unchanged drug (approximately 70%) with biliary/fecal elimination accounting for about 20-30%.
Estradiol is primarily excreted in urine (∼50%) as glucuronide and sulfate conjugates, with ∼30% excreted in feces via biliary elimination. Norethindrone is excreted mainly in urine (∼60%) as metabolites, with ∼40% in feces.
Approximately 85-90% bound to serum albumin and alpha-1-acid glycoprotein.
Estradiol is ∼98% bound to sex hormone-binding globulin (SHBG) and albumin. Norethindrone is ∼95–97% bound to SHBG and albumin.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid.
Estradiol has an apparent volume of distribution (Vd) of approximately 1.2 L/kg, indicating extensive distribution into tissues. Norethindrone has a Vd of approximately 3–5 L/kg, indicating wide distribution.
Subcutaneous bioavailability is approximately 60-70% relative to intravenous administration.
Transdermal estradiol has a bioavailability of approximately 10% relative to oral administration due to avoidance of first-pass metabolism. Oral norethindrone acetate has a bioavailability of approximately 50–60%.
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use caution and monitor; no specific dose adjustment established.
Not approved for pediatric use; safety and efficacy not established.
Not indicated for use in pediatric patients; safety and efficacy not established.
No specific dose adjustment recommended; use standard adult dosing.
Start with the lowest effective dose; monitor for thromboembolic events and cognitive effects. No specific dose adjustment required, but consider age-related renal and hepatic decline.
None
Estrogens increase the risk of endometrial cancer. There is an increased risk of cardiovascular events, breast cancer, and probable dementia with estrogen plus progestin therapy. Actively monitor for these events.
Image interpretation errors due to presence of non-specific binding or off-target uptake,Risk of misdiagnosis if used as a sole diagnostic tool,Radiation exposure risk; drug is radioactive
Cardiovascular disorders: Increased risks of stroke, myocardial infarction, and venous thromboembolism (VTE).,Malignancy: Increased risk of breast cancer, endometrial cancer, and ovarian cancer.,Probable dementia: Increased risk in women aged 65 years or older.,Gallbladder disease, hypertriglyceridemia, fluid retention, hypocalcemia, and hereditary angioedema.,Retinal thrombosis: Discontinue if sudden vision loss occurs.,Laboratory tests: May alter thyroid function tests, coagulation tests, and glucose tolerance.
Known hypersensitivity to flortaucipir or any excipient
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE) or arterial thromboembolism (ATE),Current or recent (within 1 year) VTE or ATE,Known thrombophilic disorders (e.g., protein C, S, or antithrombin deficiency; factor V Leiden mutation),Active or past history of arterial thromboembolic disease (e.g., stroke, MI),Known liver impairment or disease,Known or suspected pregnancy,Hypersensitivity to any component of the product
No specific food interactions. Patients should avoid caffeine and alcohol for 24 hours prior to the scan as they may affect brain activity, though not specifically contraindicated. Maintain normal diet but avoid heavy meals immediately before the procedure.
Grapefruit juice may increase estrogen levels by inhibiting CYP3A4; avoid excessive consumption. High-fat meals can increase absorption of oral estrogens; take consistently with or without food to maintain steady levels.
FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequate human studies exist. First trimester: theoretical risk of fetal radiation exposure (estimated fetal absorbed dose <1 m Gy from a single administration), considered minimal. Second/third trimester: radiation risk similar; no known teratogenic effects. Overall, risk is low but exposure should be avoided unless benefit clearly outweighs risk.
Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the second and third trimesters is contraindicated due to risk of fetal genital abnormalities and potential long-term neurodevelopmental effects. Avoid in pregnancy.
No data on excretion into human milk. M/P ratio unknown. Due to short physical half-life (110 minutes) and low administered activity, breastfeeding interruption of 4 hours (10 half-lives) is recommended to minimize infant radiation exposure. Alternatively, pump and discard for 4 hours post-injection.
Estradiol and norethindrone acetate are excreted into breast milk. Estradiol M/P ratio approximately 0.5; norethindrone M/P ratio approximately 0.4. May reduce milk production and alter composition. Use during breastfeeding is not recommended.
No dosing adjustment needed. The administered activity (370 MBq ±10%) is fixed; no pharmacokinetic changes in pregnancy necessitate dose alteration.
Not applicable; contraindicated in pregnancy.
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent indicated for PET imaging of tau pathology in patients with cognitive impairment being evaluated for Alzheimer's disease. Administer intravenously as a bolus injection (10 m Ci, 370 MBq). Image acquisition should begin approximately 80 minutes post-injection. False positives may occur in patients with prior strokes, brain tumors, or other causes of tau deposition. Do not use for screening or early-stage disease without cognitive symptoms. Ensure patient is well hydrated before administration. The effective radiation dose is about 7 m Sv.
For patients with an intact uterus, estrogen must be combined with a progestogen (norethindrone acetate) to prevent endometrial hyperplasia. Initiate at the lowest effective dose for the shortest duration. Avoid in women with active thromboembolic disease, known or suspected breast cancer, or undiagnosed abnormal genital bleeding. Consider transdermal route if oral absorption is compromised or for migraine with aura.
TAUVID is a radioactive tracer used to detect tau protein tangles in the brain, which are associated with Alzheimer's disease.,You will receive a single injection into a vein. The scan will start about 80 minutes after the injection and lasts approximately 30 minutes.,Drink plenty of water before the procedure to help eliminate the radioactive material from your body.,You may experience mild discomfort at the injection site, but serious side effects are rare.,The amount of radiation exposure is low and similar to other diagnostic imaging procedures, but inform your doctor if you are pregnant or breastfeeding.,Results do not provide a definitive diagnosis but help your doctor evaluate your condition.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Report any unusual vaginal bleeding, breast lumps, or symptoms of blood clots (e.g., leg pain, chest pain, sudden shortness of breath, vision changes) immediately.,Smoking increases the risk of cardiovascular side effects, especially in women over 35; avoid smoking while on this therapy.,This medication does not protect against sexually transmitted infections or HIV.,Regular medical check-ups, including breast exams and mammograms, are essential during therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAUVID vs ACTIVELLA, answered by our medical review team.
TAUVID is a Radiopharmaceutical Diagnostic Agent that works by TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.. ACTIVELLA is a Estrogen/Progestin Combination that works by Combination of estradiol, an estrogen, and norethindrone acetate, a progestin. Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which then interact with estrogen response elements on DNA, leading to changes in gene expression that regulate growth, differentiation, and function of female reproductive tissues and other tissues. Norethindrone acetate is a progestin that induces secretory changes in the endometrium, reducing the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen therapy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAUVID and ACTIVELLA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAUVID is: 18 mg intravenously once daily.. The standard adult dose of ACTIVELLA is: One tablet (1 mg estradiol + 0.5 mg norethindrone acetate) orally once daily, continuously.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAUVID and ACTIVELLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAUVID is classified as Category C. FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequ. ACTIVELLA is classified as Category C. Pregnancy Category X. Estrogen and progestin exposure during the first trimester is associated with congenital anomalies including cardiovascular and limb defects. Use during the s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.